drugset
drugset / Trial / NCT06404905

Clinical Trial of BT02 in Patients With Advanced Solid Tumors

NCT06404905 ↗

Phase 1 Recruiting 60 enrolled Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NaSingle-groupOpen-labelTreatment

Summary

A First-in-Human, Open Label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Antitumor Activity of BT02 in Patients with Advanced Solid Tumors

Timeline

Start
2024-01-24
Primary completion
2024-12-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject BT02 Monoclonal antibody — Intravenous

Indications

neoplasm